Form 4 for STOK Stoke Therapeutics, Inc.
Accepted 2026-03-12 00:00:00 ET · period of report 2026-03-10 · accession 0001586226-26-000002 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-03-12 | 2026-03-10 | STOK | TZIANABOS ARTHUR | Interim Executive COB, Dir | S - Sale+OE | $40.00 | -4,355 | 31.3K | -12% | -$174.2K |
| D | 2026-03-12 | 2026-03-10 | STOK | TZIANABOS ARTHUR | Interim Executive COB, Dir | M - OptEx | $8.33 | +3,955 | 35.7K | +12% | +$32.9K |
| D | 2026-03-12 | 2026-03-10 | STOK | TZIANABOS ARTHUR | Interim Executive COB, Dir | M - OptEx | $0.00 | -3,955 | 118.7K | -3% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-03-10 | S | D | 4,355 | $40.00 | 31,339 | D | — | — | (F2) The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.095 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 2 | Common | Common Stock | 2026-03-10 | M | A | 3,955 | $8.33 | 35,694 | D | — | — | |
| 3 | Derivative | Stock Option (Right to Buy) | 2026-03-10 | M | D | 3,955 | $0.00 | 118,696 | D | $8.33 · — to 2034-03-19 | 3,955 Common Stock | (F3) Effective October 6, 2025, this option became fully vested and exercisable. |